More recently, it has been shown that transmembrane domain targeting peptide antagonizing ErbB2/Neu exhibit anticancer properties by inhibiting breast tumor growth and metastasis in genetically engineered mouse model of breast cancer (Arpel et al., 2014). This evidence concerns the gene ERBB2 and breast carcinoma.